公开(公告)号：EP3418351A1

公开(公告)日：2018-12-26

申请号：EP17753033.4

申请日：2017-02-07

Applicant: Dexerials Corporation

Inventor： KONDO, Hirofumi ,  HATSUDA, Kouki ,  TANO, Nobuo ,  BAGHEL, Pankaj

IPC: C10M105/70 ,  C07C215/40 ,  C07D207/06 ,  C07D233/60 ,  C07D295/088 ,  C07D487/04 ,  C10M105/72 ,  G11B5/725 ,  C10N20/00 ,  C10N30/06 ,  C10N40/18

CPC classification number: C07C215/40 ,  C07D207/06 ,  C07D233/60 ,  C07D295/088 ,  C07D487/04 ,  C10M105/70 ,  C10M105/72 ,  G11B5/725

Abstract: A lubricant including an ionic liquid including a conjugate base and a conjugate acid, wherein the conjugate acid includes a group including a hydroxyl group and a group including a straight-chain hydrocarbon group having 6 or greater carbon atoms, and a pKa of an acid that is a source of the conjugate base in acetonitrile is 10 or less.

公开(公告)号：EP3215507B1

公开(公告)日：2018-12-26

申请号：EP15790141.4

申请日：2015-11-05

Applicant: Bayer Pharma Aktiengesellschaft

Inventor： PETERS, Jan-Georg ,  STIEHL, Jürgen ,  LOVIS, Kai

IPC: C07D487/04 ,  C07D233/24 ,  C07D295/088

CPC classification number: C07D487/04 ,  C07D233/24 ,  C07D265/30 ,  C07D295/088

Abstract: The present invention relates to a novel method of preparing copanlisib, and copanlisib dihydrochloride, to novel intermediate compounds, and to the use of said novel intermediate compounds for the preparation of said copanlisib.

公开(公告)号：EP3126328B1

公开(公告)日：2018-12-26

申请号：EP15712951.1

申请日：2015-03-31

Applicant: Gotion, Inc.

Inventor： GARSUCH, Arnd ,  GEYER, Karolin ,  SCHMIDT, Michael ,  MERGER, Martin ,  HOLUB, Nicole

IPC: C07C309/20 ,  C07D295/084 ,  H01G11/06 ,  H01G11/58 ,  C07C309/04 ,  C07D295/088 ,  H01G11/64 ,  H01M10/0525 ,  H01M10/0567 ,  H01M10/0569

CPC classification number: H01M10/0567 ,  C07C309/04 ,  C07C309/20 ,  C07D295/084 ,  C07D295/088 ,  H01G11/06 ,  H01G11/58 ,  H01G11/60 ,  H01G11/64 ,  H01M10/0525 ,  H01M10/0569 ,  H01M2300/0037 ,  Y02E60/13

Abstract: The present invention relates to compounds of formula (I) wherein X is N or P; -SO3- is -O-S(O)2 -or -S(O)2-O-; and n and R1 to R5 are defined below, and to their use as additives for electrolyte compositions, in particular in electrolyte compositions for lithium batteries.

公开(公告)号：EP3405183A1

公开(公告)日：2018-11-28

申请号：EP17741793.8

申请日：2017-01-13

Applicant: Arisan Therapeutics Inc.

Inventor： PLEWE, Michael ,  BROWN, Eric ,  GANTLA, Vidyasagar ,  HENKEL, Gregory ,  MCCORMACK, Kenneth ,  SOKOLOVA, Nadezda

IPC: A61K31/015 ,  A61K31/135 ,  A61K31/165 ,  C07C13/28 ,  C07C13/54 ,  C07C13/573

CPC classification number: C07D295/32 ,  A61K31/165 ,  A61K31/397 ,  A61K31/40 ,  A61K31/403 ,  A61K31/407 ,  A61K31/439 ,  A61K31/44 ,  A61K31/4465 ,  A61K31/4545 ,  A61K31/495 ,  A61K31/496 ,  A61K31/4995 ,  A61K31/5375 ,  A61K31/551 ,  C07C217/58 ,  C07C233/41 ,  C07C233/43 ,  C07C233/62 ,  C07C235/40 ,  C07C237/24 ,  C07C275/26 ,  C07C2601/14 ,  C07C2603/74 ,  C07D205/04 ,  C07D205/12 ,  C07D209/94 ,  C07D211/34 ,  C07D211/56 ,  C07D211/58 ,  C07D211/60 ,  C07D211/62 ,  C07D213/74 ,  C07D213/75 ,  C07D213/82 ,  C07D233/64 ,  C07D243/08 ,  C07D295/03 ,  C07D295/088 ,  C07D295/13 ,  C07D295/185 ,  C07D295/192 ,  C07D295/26 ,  C07D451/04 ,  C07D453/02 ,  C07D487/04 ,  C07D487/06 ,  C07D487/10

Abstract: Compounds of structural Formula (I) were developed for the treatment of infections by filoviruses including Ebolavirus and Marburgvirus.

公开(公告)号：EP3390355A1

公开(公告)日：2018-10-24

申请号：EP17707787.2

申请日：2017-02-21

Applicant: Helsinn Healthcare S.A.

Inventor： GIULIANO, Claudio ,  DAINA, Antoine ,  PIETRA, Claudio

IPC: C07C311/00 ,  C07D239/26 ,  C07C317/14 ,  C07C317/26 ,  C07D209/04

CPC classification number: C07D513/04 ,  C07C311/47 ,  C07C317/14 ,  C07C317/26 ,  C07C317/42 ,  C07C317/44 ,  C07C2601/02 ,  C07D209/04 ,  C07D209/08 ,  C07D209/44 ,  C07D213/34 ,  C07D213/76 ,  C07D215/06 ,  C07D215/08 ,  C07D215/10 ,  C07D215/58 ,  C07D217/04 ,  C07D217/10 ,  C07D223/16 ,  C07D231/56 ,  C07D233/64 ,  C07D235/14 ,  C07D237/20 ,  C07D239/26 ,  C07D239/48 ,  C07D241/04 ,  C07D241/12 ,  C07D295/088 ,  C07D307/87 ,  C07D311/76 ,  C07D317/34 ,  C07D401/12 ,  C07D403/12 ,  C07D405/04 ,  C07D405/06 ,  C07D405/12 ,  C07D409/12 ,  C07D413/12 ,  C07D417/10 ,  C07D417/12 ,  C07D471/04 ,  C07D471/08 ,  C07D487/04 ,  C07D495/04

Abstract: Benzenesulfonyl-asymmetric ureas are provided for the treatment of conditions modulated by the ghrelin receptor.

公开(公告)号：EP3383841A1

公开(公告)日：2018-10-10

申请号：EP16871454.1

申请日：2016-11-30

Applicant: The Arizona Board of Regents On Behalf of the University of Arizona

Inventor： HURLEY, Laurence ,  GOKHALE, Vijay ,  KANG, HyunJin ,  WU, Kui

IPC: C07C275/54 ,  A01N47/34 ,  A61K31/17 ,  C07D401/12

CPC classification number: C07C275/54 ,  A61P35/00 ,  C07D219/08 ,  C07D239/34 ,  C07D239/52 ,  C07D241/18 ,  C07D295/088 ,  C07D401/12 ,  C07D403/04

Abstract: The present invention provides hTERT modulators and methods for producing and using the same. In particular, the present invention provide a compound of the formula as described herein. Some aspects of the invention are based on the characterization of the effect of hTERT core promoter region mutants on the 5-12 G-quadruplex structure and its stability. It is believed that some of the compounds of the invention bind selectively to the G-quadruplex in the hTERT core promoter mutant, which results in reversal of the effect of mutant promoter activation.

公开(公告)号：EP2799427B1

公开(公告)日：2018-07-04

申请号：EP14173039.0

申请日：2007-07-05

Applicant: Fibrotech Therapeutics PTY LTD

Inventor： Williams, Spencer John ,  Stapleton, David ,  Zammit, Steven ,  Kelly, Darren James ,  Gilbert, Richard Ernest ,  Krum, Henry

IPC: C07C235/38 ,  A61P13/12 ,  C07D213/643 ,  A61K31/435 ,  A61P35/00 ,  A61P11/00 ,  C07D213/16 ,  A61K31/426 ,  A61P29/00 ,  C07D295/03 ,  C07C231/02 ,  A61K31/4192 ,  C07D261/08 ,  A61P9/10 ,  A61K31/196 ,  A61P17/02 ,  C07D253/04 ,  A61K31/5375 ,  A61P43/00

CPC classification number: A61K31/196 ,  A61K31/4192 ,  A61K31/42 ,  A61K31/4409 ,  A61K31/5375 ,  C07C235/38 ,  C07C237/20 ,  C07C237/30 ,  C07C2601/08 ,  C07C2601/14 ,  C07C2602/42 ,  C07C2602/44 ,  C07C2603/74 ,  C07D213/30 ,  C07D213/56 ,  C07D213/64 ,  C07D249/04 ,  C07D261/08 ,  C07D265/22 ,  C07D295/088 ,  C07D295/108

Abstract: The present invention provides substituted cinnamoyl anthranilate compounds exhibiting anti-fibrotic activity; or derivatives thereof, analogues thereof, pharmaceutically acceptable salts thereof, and metabolites thereof; with the proviso that the compound is not Tranilast.

公开(公告)号：EP2794009B1

公开(公告)日：2017-08-30

申请号：EP12806515.8

申请日：2012-12-21

Applicant: Kancera AB

Inventor： MARTINSSON, Jessica ,  FÄRNEGÅRDH, Katarina ,  JÖNSSON, Mattias ,  RINGOM, Rune

IPC: A61P35/00 ,  A61P29/00 ,  A61K31/381 ,  A61K31/41 ,  A61K31/18 ,  A61K31/343 ,  A61K31/427 ,  A61K31/4436 ,  A61K31/506 ,  C07C311/13 ,  C07C311/21 ,  C07C311/27 ,  C07C311/29 ,  C07C311/39 ,  C07C311/46

CPC classification number: C07D409/14 ,  C07C311/21 ,  C07C2601/16 ,  C07D213/34 ,  C07D213/71 ,  C07D213/74 ,  C07D215/12 ,  C07D231/38 ,  C07D261/14 ,  C07D277/26 ,  C07D285/15 ,  C07D295/088 ,  C07D295/096 ,  C07D295/192 ,  C07D307/64 ,  C07D307/79 ,  C07D307/82 ,  C07D333/22 ,  C07D333/34 ,  C07D333/62 ,  C07D405/04 ,  C07D409/04 ,  C07D409/12

公开(公告)号：EP2666773B1

公开(公告)日：2017-07-26

申请号：EP12736637.5

申请日：2012-01-11

Applicant: Jiangsu Hansoh Pharmaceutical Co., Ltd. ,  Jiangsu Hansoh Medicine Institute Co., Ltd. ,  Jiangsu Hansoh Pharmaceutical Group Co., Ltd.

Inventor： PAN, Bigao ,  HUANG, Longbin ,  YANG, Baohai

IPC: C07D413/10 ,  A61K31/4245 ,  A61P9/12

CPC classification number: C07D413/10 ,  A61K31/4245 ,  C07C213/08 ,  C07C215/08 ,  C07C215/40 ,  C07D295/088

公开(公告)号：EP3013346A4

公开(公告)日：2016-11-02

申请号：EP14817212

申请日：2014-06-26

Applicant: KOREA INST SCI & TECH

Inventor： KIM DONG JIN ,  KIM YOUNG SOO ,  KIM HYE YUN ,  KIM HYUN JIN

IPC: A61K31/5375 ,  A61K31/445 ,  A61K31/4965 ,  A61P25/16

CPC classification number: C07D295/15 ,  A61K31/495 ,  A61K31/5375 ,  C07D295/088

Abstract: Provided is a pharmaceutical composition for preventing or treating a cognitive impairment-related disease, the pharmaceutical composition including N-(2-hydroxyethyl)piperazine-N′(3-propane sulfonic acid), a pharmaceutically acceptable salt thereof or a derivative thereof, and donepezil, a pharmaceutically acceptable salt thereof or a derivative thereof. The composition may be used in preventing or treating a cognitive impairment-related disease.